January 28, 2026
1 min read

Cellares’ series D round draws $257M as cell therapy contractor takes operations global

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

Leave a Reply

Your email address will not be published.

Previous Story

Antheia seals 2nd series C funding close, hitting more than $175M in a year

Next Story

From the community | MAHA is worsening nutrition insecurity — ‘Food is Medicine’ can do better

Previous Story

Antheia seals 2nd series C funding close, hitting more than $175M in a year

Next Story

From the community | MAHA is worsening nutrition insecurity — ‘Food is Medicine’ can do better

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop